Introduction
The E1a gene from adenovirus has been related to several biological processes, such as apoptosis, differentiation and oncogenesis. However, probably one of the most amazing aspects of this gene is the ability to induce opposite effects such as proliferation and apoptosis (Gallimore and Turnell, 2001) , or transformation and tumor suppression (Frisch, 2001; Frisch and Mymryk, 2002) . From the therapeutic point of view it is important to note that one of the most interesting aspects is the possibility of inducing chemo-and radio-sensitivity by E1a expression (Sanchez-Prieto et al., 1996) . Few data are known about the ability to induce chemo/radio-sensitivity that seems to be mediated through inactivation of the NF-kB for g-radiation (Shao et al., 1997) , while no definitive clue has been established in terms of chemotherapy. No clear relationship has been established between E1a and the signal transduction pathways related to chemo-and radiotherapy such as Stress Activated Protein Kinase (SAPK) and PI3K/ Akt. Only the Extracellular Regulated Kinase (ERK) pathway seem to be interacting with E1a through phosphorylation (Whalen et al., 1997) .
With regard to the SAPK pathway, Jun-NHTerminal Kinase (JNK) and P38 Mitogen Activated Protein kinase (MAPK) family, no relationship has been proven with E1a, only the E1b gene has been shown to affect the JNK pathway (See and Shi, 1998) .
The PI3K/Akt pathway, whose main role seems to be the induction of survival by apoptotic signal inhibition, has never been connected to E1a expression, although recent evidences suggest a basal downregulation with no apparent effect in terms of radiosensitivity (Shao et al., 2001) .
All the previously indicated signaling pathways are implicated in apoptosis, oncogenesis, cell growth and cellular response to chemo-and radiotherapy, cellular processes also affected by E1a. Therefore we decided to study whether E1a expression could affect some of the above-mentioned signaling pathways and also if we could explain some of the biological properties associated to E1a expression. Our data demonstrate that the Akt pathway is affected and could explain induction of chemosensitivity.
Results and Discussion
E1a induces a selective blockage of the PI3K/Akt pathway In order to study if the signaling pathways related to chemo-and radiotherapy could be affected by E1a expression, IMR90 cells were infected with a retroviral vector coding for E1a 12S (pLPC E1a) or Enhanced Green Fluorescent Protein (EGFP) (pLPC EGFP). Cells were treated with different stimuli for several signal transduction pathways. For JNK and p38 MAPK, cells were treated with 20 mg/ml cisplatin (CDDP). Activation of JNK and p38 was analysed by immunoblotting against phosphorylated forms. No difference was observed in the p38 MAPK pathway and a slight increase in the JNK pathway ( Figure 1a ,b). It is important to note that all these experiments were also performed in transient trans-fection using Cos-7 cells with JNK and p38MAPK hemagglutinin tagged (HA). Overexpression of E1a did not alter the activity of any of these kinases with or without treatment (data not shown). In order to see if E1a expression was able to interfere with the Akt signaling pathway, we used a well-known stimuli for Akt activation such as insulin (Alessi et al., 1996) . IMR90 cells were starved overnight (o/n) and treated with insulin (100 nM) for 30 min. While IMR90 EGFP cells showed an increase in Akt activation similar to IMR90 cells, cells expressing E1a showed a weaker increment. This data indicates that the E1a gene is able to partially block the Akt mediated signaling pathway, at least when insulin is used as a stimuli.
To confirm this observation we decided to use transient transfection in Cos-7 cells. Cells were transfected with wt Akt tagged with HA epitope (HA-Akt) in the presence of EGFP or E1a 12S. Clearly E1a blocks the insulin mediated Akt activation in similar conditions to IMR90 (Figure 2a) . Insulin was able to induce Akt activation in a dose dependent fashion (Figure 2b ), also E1a was able to block Akt insulin mediated activation in a dose dependent manner ( Figure 2b ). Several stimuli are known to activate Akt, among them v-H-ras oncogenic protein.
In this case the activation mechanism is very well established through direct binding to the catalytic subunit of PI3K, p110 (Rodriguez-Viciana et al., 1994) . In order to see if E1a was able to block this interaction, Cos-7 cells were transfected with pLPC vector coding for EGFP, v-H-ras or v-H-ras and E1a, linked by IRES sequence in the presence of HA-Akt. In this case, E1a was unable to affect v-H-ras dependent activation (Figure 2c ), indicating that E1a is acting probably upstream of the catalytic subunit of PI3K complex. Taking into account that E1a is able to downregulate some tyrosine kinase receptors such as Axl or Neu (Lee et al., 1999; Yu et al., 1990) , we decided to exclude the possibility of downregulation of the insulin receptor by performing immunoblotting and RT -PCR studies. As is shown in Figure 2d , cells overexpressing E1a showed a slight increase in the amount of the receptor, similar results were obtained using RT -PCR (data not shown), in agreement with previous studies (Kim et al., 1995) . Furthermore, to assess the pathway functionality we measured the insulin mediated activation of another pathway such as ERK1/2 (for a review see Saltiel and Kahn, 2001) . MAPK activation was almost abolished in IMR90 E1a cells (Figure 2e ), indicating that the functionality of the receptor or immediate downstream target is probably affected by the E1a expression.
E1a downregulates Akt basal status of phosphorylation
Recently, it has been reported that E1a is able to block basal activity of Akt in the human ovarian cancer cell line SKOV-3 (Shao et al., 2001) . In order to study if this phenomenon also takes place in our experimental model, cells were plated and, after 24 h in the presence of serum, were starved for another 12 and 24 h. Clearly, in the presence of serum IMR90 cells expressing E1a showed a lower level of phospho Akt, Figure 1 (a) Cell lines were established by retroviral infection using the packaging cell line Phoenix Amphotropic. Phoenix Amphotropic cells were transfected by calcium phosphate with pLPC EGFP or pLPC E1a (kindly supplied by Dr M Serrano, CNB, Madrid), supernatant was removed after 48 h and used to infect the IMR90 cells for 6 h in the presence of Polibrene (Sigma). Two days later, cells were selected with the appropriate dose of Puromycin (Clontech). Before experiments, antibiotic containing medium was replaced with regular medium. Subconfluent cultures of IMR90 cells with EGFP or with E1a expression were treated with different stimuli for different signaling pathways using antibodies to phosphorylated forms of JNK, p38 MAPK, Akt (Cell Signaling Technologies). Cells were treated and collected in lysis buffer (25 mM HEPES pH 7.5, 0.3 M NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 1% Triton X-100, 0.1% SDS, 0.5% deoxycholic acid, 20 mM b-glycerophosphate) in the presence of protease and phosphatase inhibitors (20 mg/ml aprotinin, 20 mg/ml leupeptin, 1 mM PMSF and 0.1 mM Na 3 VO 4 ). Antibody detection was achieved by enhanced chemiluminescence (Amersham), according to the manufacturer's protocol. Cells were treated with 20 mg/ml cisplatin from Bristol Myers for 3 h and then p38 MAPK activity was evaluated from total cell lysates. (b) Cells were treated with cisplatin (20 mg/ml), for 3 h and then JNK activity was evaluated from total cell lysates. (c) IMR90 EGFP or E1a cells were o/n starved and then treated with 100 nM insulin (Actrapid, Novo Nordisk) for 30 min. Total cell lysates were blotted against phosphorylated Akt in Serine 473. The figure shows the most representative of three experiments with similar results. As a control, all membranes were reblotted against the non-phosphorylated form of each kinase (Santa Cruz Biotechnology) however, after starving for 12 h both cell lines showed similar levels of Akt phosphorylation (Figure 3a) , corroborating our first observation (Figure 1d ). This result supports the idea that E1a is constitutively downregulating the Akt pathway.
In order to assess if the phenomenon observed after treatment with insulin was only restricted to human normal fibroblasts we decided to test another cell line, such as A431, and also in 293T cells. A431 cells in the presence of E1a clearly showed a reduction of Akt activation after insulin treatment, presenting a similar pattern to IMR90 (Figure 3b) . However, 293T cells with a high expression of E1a gene showed a moderate increase in Akt phosphorylation after treatment with insulin (Figure 3c ), but no comparison could be established without E1a expression. This last result supports the fact that E1a does not completely abolish the activation of Akt.
E1a induces sensitivity to cisplatin
One of the most widely known features of the E1a gene is the ability to induce sensitivity to DNA damaging agents such as cisplatin (Sanchez-Prieto et al., 1996) . We decided to test this hypothesis in our experimental model of IMR90 cells with and without E1a 12S expression. It is important to emphasize that E1a 12S is capable of inducing sensitivity in the context of wt p53 (Teodoro et al., 1995) , which is present in IMR90 cells. Cells expressing E1a clearly showed a marked sensitivity to cisplatin as is demonstrated in the dose response assay (Figure 4a) . Recent evidence suggests a role for the Akt pathway in response to chemotherapy and radiotherapy in several human tumor models (Hayakawa et al., 2000; Mitsuuchi et al., 2000) . To analyse the role of Akt in the sensitivity induced by E1a to cisplatin, we decided to measure the Akt activation by cisplatin in our model of IMR90 fibroblasts. Cells were incubated with cisplatin (60 and 120 mg/ml) for 5 h and Akt activity was determined by kinase assay. While there is an increase in Akt activity in the IMR90 cells, cells with E1a expression showed a lack of activation by cisplatin Figure 2 (a) Cos-7 cells were transfected using Lipofectamine (Invitrogene) following the manufacturer's instructions, with 0.5 mg of pCEFL HA-Akt (kindly supplied by Dr S Gutkind, NIDCR, NIH, Bethesda, Maryland), plus 2 mg of pLPC EGFP or pLPC E1a per 60 mm dish. Thirty-six hours after transfection cells were o/n starved and then stimulated for 30 min with 100 nM insulin. Samples were immunoprecipitated with anti HA (1 mg/ sample) from Santa Cruz Biotech. After a minimum of 2 h, extracts were incubated for 45 min in the presence of protein G (Gamma Bind Sepharose, Pharmacia Biotech) and then washed three times in the same lysis buffer. Then immunocomplexes were re-suspended in loading buffer. E1a expression was determined using E1a antibody (Oncogene Science, clone M73). As a loading control membranes were blotted against HA. (b) Cos-7 cells transfected with 0.5 mg of HA-Akt were treated with increasing amounts of insulin (100 -400 nM), Akt was activated in a dose-dependent manner. Cos-7 cells were transfected with 0.5 mg HA-Akt in the presence/absence of increasing amounts of pLPC E1a (1 -4 mg) per 60 mm dish and treated with the maximum dose of insulin (400 nM). E1a clearly diminishes Akt activation. As a loading control membranes were blotted against HA. (c) Cos-7 cells were transfected with HA-Akt (0.5 mg) per 60 mm dish plus 2 mg of pLPC EGFP, pLPC v-H-Ras, pLPC E1a IRES v-HRas or pLPC E1a (kindly supplied by Dr M Serrano, CNB, Madrid). As a loading control membranes were blotted against HA. (d) Immunoblotting analysis was performed against the insulin receptor (a subunit, Santa Cruz Biotech.). (e) IMR90 EGFP or E1a cells were treated with insulin (100 nM) for 5 min. Total cell lysates were blotted against phosphorylated ERK1/2 (Cell Signaling Technologies). Membranes were probed against ERK1 (Santa Cruz Biotech.) as a loading control. The figure shows the most representative of three experiments with similar results (Figure 4b ). This result indicates that the inhibition of Akt activity is not only caused by insulin, in fact cisplatin presents the same pattern. Moreover, this latter result indicates a correlation between a lack of Akt activity and a phenotype that is chemo-sensitive to cisplatin. Recent evidences suggest that inhibition of the PI3K pathway is related to the induction of chemoand radio-sensitivity. We decided to study this issue in our experimental model of IMR90 cells using PI3K inhibitors (LY294002 and Wortmannin). Cells were plated and 24 h later pre-treated for 1 h with the PI3K inhibitor LY294002 (20 mM) and then incubated with cisplatin (doses ranging from 10 to 40 mg/ml) for 24 h. The presence of PI3K inhibitor clearly induces sensitivity to cisplatin in IMR90 cells (Figure 4c) , as has been previously described for other systems (Ng et al., 2001 ). This sensitivity is lower than that induced by E1a (Figure 4a,c) , probably indicating that other mechanism/s should be considered. However, this data supports the fact that PI3K/Akt modulation is determinant in the response to cisplatin and that E1a mediated blockage can be a potential mechanism for the sensitive phenotype.
Regulation of Akt through E1a
Several conclusions can be drawn from the results presented in this study. First, E1a expression is capable of selectively blocking the PI3K/Akt pathway implicated in survival, but not other pathways that are implicated in cellular stress, such as the SAPK, without 4 cells/well of IMR90 EGFP (solid square) or E1a (solid circle) were plated 24 h prior to treatment with cisplatin (doses ranging from 1 to 20 mg/ml). Viability was assayed by the crystal violet method. Briefly, cells were then fixed in glutaraldehyde 2% for 20 min, washed twice in PBS and stained with crystal violet for 20 min, and then washed with abundant deionized water. Colorant was recovered by 1% acetic acid and OD was evaluated at 590 nm. This was the most representative of three experiments performed in triplicate with similar results. The SEs in triplicate samples were lower than the symbol size. (b) Endogenous Akt was immunoprecipitated after a 5-h treatment with 60 or 120 mg/ml of cisplatin and subjected to kinase assay using a Cell Signalling Technologies kit for Akt kinase assay. Cells were processed as in the immunoprecipitation procedure and immunocomplexes were incubated with GST-GSK3 in kinase buffer. Samples were then loaded on to 15% SDS -PAGE and blotted against the phosphorylated form of GSK3. (c) 5610 4 cells/well of IMR90 were plated 24 h prior to treatment with cisplatin. Cells were pretreated for 1 h with 20 mM LY294002 (Cell Signalling Technologies) (solid square) or similar amounts of DMSO (solid circle) and then incubated with cisplatin (doses ranging from 1 to 20 mg/ml). The presence of Ly294002 induced marked sensitivity. Similar results were obtained with wortmannin (data not shown). This was the most representative of three experiments performed in triplicate with similar results. The s.e. in triplicate samples were lower than the symbol size Figure 3 (a) IMR90 cells with EGFP or E1a expression were grown in the presence of 10% FBS or starved for 12 -24 h. Total cell lysates were collected and subjected to immunoblot against the active form of Akt. (b) A431 cells expressing EGFP or E1a were generated as IMR90 EGFP or E1a. Cells were o/n starved and then treated with 100 nM insulin for 30 min and Akt activation was measured by immunoblotting. (c) 293T cells were starved for 24 h and then treated with 100 or 400 nM insulin for 30 min. Akt activation was measured by immunoblotting. As a loading control total amount of Akt was measured. The figure shows the most representative of three experiments with similar results E1a blocks Akt activation J Guinea Viniegra et al apparent transcriptional repression. Moreover, IMR90 cells expressing E1a showed lower Akt phosphorylation in normal growth conditions (10% FBS), as has been reported previously (Shao et al., 2001) . However, it is important to note that in cell lines such as 293 or its derivates, with a high expression of E1a, Akt can be activated in response to insulin (this study and Alessi et al., 1996) , indicating that E1a is not completely able to abolish the Akt activation, and that other issues, probably cell type specific, should be considered. E1a has been linked to apoptosis and the inhibition of a survival pathway fits this biological property perfectly. Our data demonstrates that biological properties associated with E1a expression, such as apoptosis or sensitivity to cisplatin, do not seem to be mediated by interference with the SAPK (p38 MAPK and JNK) pathway. Second, E1a is also related to an anti-tumor effect in vivo as has been shown in several cell systems (Frisch, 2001) . The inhibition of Akt could fit perfectly with the tumor suppression activity of E1a, as has been proposed for other natural Akt inhibitors such as pTEN/MAC or CTMP, which are known to be tumor suppressor genes (Maira et al., 2001; Simpson and Parsons, 2001) . However, E1a is capable of inducing transformation in cooperation with other oncogenes, such as v-H-ras (Franza et al., 1986) . In this oncogene cooperation model, E1a is one of the key components. Our data demonstrates that there is no blockage of Akt activation in the presence of v-H-ras, thereby supporting this experimental model. Third, from the mechanistic point of view, our data indicates that the inhibition is upstream of the catalytic subunit p110 of PI3K, due to the fact that v-H-ras activates Akt by direct interaction with p110 (Rodriguez-Viciana et al., 1994) . Interestingly, E1a has been shown to downregulate some tyrosine receptor kinases (Lee et al., 1999; Yu et al., 1990) , but in our model of E1a-expressing cells we were able to detect an increase in the insulin receptor by immunoblotting and RT -PCR. Some reports have indicated a connection between E1a and the insulin receptor and insulin gene. While upregulation of the receptor has been reported (Kim et al., 1995) , others have indicated an inhibition of the insulin gene enhancer or the transcriptional effects of insulin (Guo et al., 2001; Stein and Whelan, 1989) . The lack of MAPK activation after insulin treatment in E1a expressing cells probably indicates that molecules, or the functionality of these molecules, upstream the catalytic subunit, of the PI3K complex, are affected by E1a expression. Among them p85, insulin receptor or insulin receptor substrates should be considered. In summary, our data support a clear inhibitory role for E1a in the insulin pathway in terms of signaling. Further studies are necessary to define this inhibitory regulation mediated by E1a in response to Akt activation.
Finally, activation of PI3K/Akt is implicated in a phenotype resistant to cisplatin (Mitsuuchi et al., 2000; Brognard et al., 2001) , and therefore inhibition of the PI3K/Akt can render sensitivity and partially explain the marked sensitivity to cisplatin induced by E1a. From the clinical point of view, one of the most important properties of E1a is the marked sensitivity to treatment with DNA-damaging agents. This issue has been explained by interference with the NF-kB pathway (Shao et al., 1997) . Here we present evidence that inhibition of the Akt pathway is also related to the chemo-sensitive phenotype associated with cisplatin treatment. It has recently been reported that E1a is able to induce radio sensitivity in SKOV-3 cells by interference with the NF-kB pathway without implication of the PI3K/Akt pathway (Shao et al., 2001) . At least two differences should be mentioned. First, we used cisplatin that has a totally different action mechanism to g-radiation, and second, we used a human normal cell line, while the transformed ovarian carcinoma cell line SKOV3 is known for the overexpression and constitutively active PI3K (Razzini et al., 2000; Shayesth et al., 1999) . Our data using PI3K inhibitors, such as LY294002, supports the fact that Akt inhibition is a putative mechanism to induce sensitivity to cisplatin, but not as effective as E1a. Therefore, inhibition of the PI3K/Akt pathway is probably one of the several mechanisms affected by E1a to induce a sensitive phenotype to cisplatin.
Thus, to summarize, we have demonstrated that E1a 12S selectively interferes with the PI3K/Akt pathway, without affecting other signaling pathways such as SAPK (JNK or P38 MAPK) implicated in genotoxic stress. This effect has been observed in response to a variety of stimuli such as insulin or cisplatin, and also under basal conditions. Our results suggest that Akt inhibition explain some of the biological properties of the E1a gene with implications in cancer therapy such as sensitivity to cisplatin.
